We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 06, 2022

Real-World Association Between SGLT2 Inhibitor Use and Hospitalisations for Heart Failure in Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Sodium-glucose co-transporter-2 (SGLT2) inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies
Diabetes Obes Metab 2022 Oct 14;[EPub Ahead of Print], W Hinton, AS Ansari, MB Whyte, AP McGovern, MD Feher, N Munro, S de Lusignan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading